QGC 001

Drug Profile

QGC 001

Alternative Names: Amino butane sulfonate disulfure; QGC-011; QGC001; RB 150

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CNRS; INSERM; University Paris Descartes
  • Developer Quantum Genomics
  • Class Amines; Aminopeptidases; Antihypertensives; Disulfides; Metalloexopeptidases; Sulfonic acids
  • Mechanism of Action Glutamyl aminopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure; Hypertension

Most Recent Events

  • 13 Oct 2017 Phase-II clinical trials in Hypertension in USA (PO) (NCT03198793)
  • 29 Jun 2017 Quantum Genomics plans a phase II trial for Hypertension in USA, in September 2017 (NCT03198793)
  • 16 Jun 2017 Efficacy and safety data from a phase II trial in Hypertension presented at the 27th European Meeting on Hypertension and Cardiovascular Protection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top